TRVI
Price
$8.38
Change
-$0.17 (-1.99%)
Updated
Sep 23, 04:59 PM (EDT)
Capitalization
1.02B
42 days until earnings call
XENE
Price
$37.31
Change
-$0.04 (-0.11%)
Updated
Sep 23, 04:59 PM (EDT)
Capitalization
2.88B
42 days until earnings call
Interact to see
Advertisement

TRVI vs XENE

Header iconTRVI vs XENE Comparison
Open Charts TRVI vs XENEBanner chart's image
Trevi Therapeutics
Price$8.38
Change-$0.17 (-1.99%)
Volume$27.23K
Capitalization1.02B
Xenon Pharmaceuticals
Price$37.31
Change-$0.04 (-0.11%)
Volume$20.6K
Capitalization2.88B
TRVI vs XENE Comparison Chart in %
Loading...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
TRVI vs. XENE commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TRVI is a Buy and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (TRVI: $8.55 vs. XENE: $37.35)
Brand notoriety: TRVI and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: TRVI: 61% vs. XENE: 103%
Market capitalization -- TRVI: $1.04B vs. XENE: $2.88B
TRVI [@Biotechnology] is valued at $1.04B. XENE’s [@Biotechnology] market capitalization is $2.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.23B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TRVI’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • TRVI’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, TRVI is a better buy in the long-term than XENE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TRVI’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).

  • TRVI’s TA Score: 5 bullish, 4 bearish.
  • XENE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TRVI is a better buy in the short-term than XENE.

Price Growth

TRVI (@Biotechnology) experienced а +6.01% price change this week, while XENE (@Biotechnology) price change was +3.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.94%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +48.45%.

Reported Earning Dates

TRVI is expected to report earnings on Nov 05, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.88B) has a higher market cap than TRVI($1.02B). TRVI YTD gains are higher at: 107.524 vs. XENE (-4.719). TRVI has higher annual earnings (EBITDA): -47.19M vs. XENE (-315.5M). XENE has more cash in the bank: 488M vs. TRVI (204M). TRVI has less debt than XENE: TRVI (891K) vs XENE (8.72M). XENE has higher revenues than TRVI: XENE (7.5M) vs TRVI (0).
TRVIXENETRVI / XENE
Capitalization1.02B2.88B35%
EBITDA-47.19M-315.5M15%
Gain YTD107.524-4.719-2,278%
P/E RatioN/AN/A-
Revenue07.5M-
Total Cash204M488M42%
Total Debt891K8.72M10%
FUNDAMENTALS RATINGS
TRVI vs XENE: Fundamental Ratings
TRVI
XENE
OUTLOOK RATING
1..100
2071
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
3639
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3955
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
2090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (43) in the Pharmaceuticals Major industry is in the same range as XENE (74) in the Biotechnology industry. This means that TRVI’s stock grew similarly to XENE’s over the last 12 months.

TRVI's Profit vs Risk Rating (36) in the Pharmaceuticals Major industry is in the same range as XENE (39) in the Biotechnology industry. This means that TRVI’s stock grew similarly to XENE’s over the last 12 months.

TRVI's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as XENE (97) in the Biotechnology industry. This means that TRVI’s stock grew similarly to XENE’s over the last 12 months.

TRVI's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as XENE (55) in the Biotechnology industry. This means that TRVI’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for TRVI (100) in the Pharmaceuticals Major industry. This means that XENE’s stock grew significantly faster than TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TRVIXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
73%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 8 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYCOX66.000.36
+0.55%
Rydex NASDAQ-100® C
ZEMAX14.440.03
+0.21%
American Beacon Ninety One Emr Mkts Eq Y
SVACX6.43N/A
N/A
Federated Hermes Strategic Value Div C
WBBIX10.64N/A
N/A
TETON Westwood Balanced I
LGOFX33.85-0.04
-0.12%
Lord Abbett Growth Opportunities F

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with BIESF. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
+4.91%
BIESF - TRVI
43%
Loosely correlated
N/A
PTGX - TRVI
40%
Loosely correlated
+3.71%
GOSS - TRVI
29%
Poorly correlated
+3.61%
XENE - TRVI
28%
Poorly correlated
+1.08%
FATE - TRVI
28%
Poorly correlated
+4.96%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+1.08%
IDYA - XENE
57%
Loosely correlated
+0.70%
CRNX - XENE
54%
Loosely correlated
-0.56%
IMVT - XENE
52%
Loosely correlated
+5.48%
NRIX - XENE
52%
Loosely correlated
-0.12%
ATXS - XENE
51%
Loosely correlated
+6.52%
More